Expert report on neoadjuvant immune checkpoint inhibitors for Melanoma

0 Views

07/09/23

Olivier Michielin discusses abstracts presented at ESMO Congress 2022:
- LBA6: Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
- LBA39: Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)

Produced by the European Society for Medical Oncology
http://oncologypro.esmo.org

This video was supported with an educational grant from Roche.
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.